Fernand Labrie
Publications
Page 5 of 8, showing 50 records out of 368 total, starting on record 201, ending on 250
| Publication | Category | Year |
|---|---|---|
| 204. Dupont, A., Labrie, F., Giguère, M., Borsanyi, J.-P., Lacourcière, Y., Bélanger, A., Lachance, R., Emond, J., Monfette, G. (1988) Combination therapy with Flutamide and castration (orchiectomy or LHRH agonist) in untreated patients with advanced prostate cancer, in: Höffken, K., ed. LHRH agonists in Oncology. Symposium on GnRH Analogues, Essen, pp 60-71. | Prostate Cancer | 1988 |
| 203. Dupont, A., Labrie, F., Giguere, M., Borsanyi, J.-P., Lacourcière, Y., Bergeron, N., Cusan, L., Bélanger, A., Emond, J. (1988) Combination therapy with Flutamide and [D-Trp6]LHRH ethylamide for stage C prostatic carcinoma. Eur. J. Cancer Oncol., 24: 659-666. | Prostate Cancer | 1988 |
| 74. Eeles, R.A., Durocher, F., Edwards, S., Teare, D., Badzioch, M., Hamoudi, R., Gill, S., Biggs, P., Dearnaley, D., Ardern-Jones, A., Dowe, A., Shearer, R., McLennan, D.L., Norman, R.L., Ghadirian, P., Aprikian, A., Ford, D., Amos, C., King, T.M., The Cancer Research Campaign/British Prostate Group U.K. Familial Prostate Cancer Study Collaborators, Labrie, F., Simard, J., Narod, S.A., Easton, D., Foulkes, W.D. (1998) Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am. J. Hum. Genet, 62: 653-658. | Prostate Cancer | 1998 |
| 312. Faure, N., Labrie, F., Belanger, A., Lemay, A., Raynaud, J.P., Von der Ohe, M., Fazekas, A.T. (1982) Sensitivity of luteinizing hormone and gonadal steroid responses to single intranasal administration of an LHRH agonist (HOE-766) in young normal adult men. J. Endocrinol. Invest., 5: 355-360. | Prostate Cancer | 1982 |
| 313. Faure, N., Labrie, F., Lemay, A., Bélanger, A., Gourdeau, Y., Laroche, B., Robert, G. (1982) Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent LHRH agonist in adult men. Fertil. Steril., 37: 416-424. | Prostate Cancer | 1982 |
| 320. Faure, N., Lemay, A., Bélanger, A., Labrie, F. (1981) Inhibition of androgen biosynthesis in the human male by chronic administration of [D-Ser(TBU)6]-des-Gly-NH210]LHRH ethylamide, in: Zatuchni, G.I., Shelton, J.D. et Sciarra, J.J., eds: LHRH peptides as female and male contraceptive, Philadelphia, Harper & Row, pp 307-320. | Prostate Cancer | 1981 |
| 282. Faure, N., Lemay, A., Tolis, G., Labrie, F., Bélanger, A., Fazekas, A.T.A. (1984) Buserelin therapy for prostatic carcinoma, in: Vickery, B.H., Nestor, J.J. et Hafez, E.S.E., eds: LHRH and its analogs: contraceptive and therapeutic applications, Boston, MTP Press, pp 337-349. | Prostate Cancer | 1984 |
| 351. Ferland, L., Labrie, F., Savary, M., Beaulieu, M., Coy, D.H., Coy, E.J., Schally, A.V. (1976) Inhibitory activity of analogues of luteinizing hormone-releasing hormone (LH-RH) in vitro and in vivo. Clin. Endocrinol. (Oxf.), 5: 279S-289S. | Prostate Cancer | 1976 |
| 250. Harnois, C., Malenfant, M., Dupont, A., Labrie, F. (1986) Ocular toxicity of Anandron in patients treated for prostatic cancer. Br. J. Ophthalmol., 70: 471-473. | Prostate Cancer | 1986 |
| 205. Labrie, C., Bélanger, A., Labrie, F. (1988) Androgenic activity of dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 123: 1412-1417. | Prostate Cancer | 1988 |
| 232. Labrie, C., Cusan, L., Plante, M., Lapointe, S., Labrie, F. (1987) Analysis of the androgenic activity of synthetic "progestins" currently used for the treatment of prostate cancer. J. Steroid Biochem., 28: 379-384. | Prostate Cancer | 1987 |
| 181. Labrie, C., Simard, J., Marchetti, B., Pelletier, G., Zhao, H.F., Bélanger, A., Labrie, F. (1989) Conversion of precursor adrenal steroids into potent androgens in peripheral tissue, in: Labrie, F., Lee, F. et Dupont, A., eds: Early Stage Prostate Cancer: Diagnosis and Choice of Therapy, North Holland, Elsevier, ICS 841, pp 1-22. | Prostate Cancer | 1989 |
| 182. Labrie, C., Simard, J., Zhao, H., Bélanger, A., Pelletier, G., Labrie, F. (1989) Stimulation of androgen-dependent gene expression by the adrenal precursors dehydroepiandrosterone and androstenedione in the rat ventral prostate. Endocrinology, 124: 2745-2754. | Prostate Cancer | 1989 |
| 321. Labrie, F. (1981) Changing the message from the brain. People, 8: 16-17. | Prostate Cancer | 1981 |
| 303. Labrie, F. (1983) A new therapy in prostatic cancer. Urology Times, August. | Prostate Cancer | 1983 |
| 304. Labrie, F. (1983) Luteinizing hormone-releasing hormone agonists and fertility regulation. The 9th Jennifer Hallam Memorial Lecture. J. Obst. Gynecol., 3: S37-S46. | Prostate Cancer | 1983 |
| 283. Labrie, F. (1984) A new approach in the hormonal treatment of prostate cancer: complete instead of partial blockade of androgens. Int. J. Androl., 7: 1-4. | Prostate Cancer | 1984 |
| 284. Labrie, F. (1984) Résultats exceptionnels d'un nouveau traitement du cancer de la prostate. Interface, 5: 23-25. | Prostate Cancer | 1984 |
| 271. Labrie, F. (1985) Dreijahrige erfahrungen mit der Kombinations-therapie von Flutamid und einem LHRH-agonisten leuprolide beim Prostatakarzinom. Der Urologe. Ausg. B., B6: 342-343. | Prostate Cancer | 1985 |
| 272. Labrie, F. (1985) LHRH et ses agonistes: applications thérapeutiques. Médecine/Sciences, 1: 300-305. | Prostate Cancer | 1985 |
| 233. Labrie, F. (1987) Tratamiento del cancer de prostata mediante bloqueo hormonal completo, in: Carcinoma de Prostata: Avances en el Tratamiento Hormonal Patrocinado por la Asociacion Espanola de Urologia Barcelona, pp 61-67. | Prostate Cancer | 1987 |
| 183. Labrie, F. (1989) Criteria of response of stage D2 prostate cancer [Letter to the Editor: Reply to Newling et al. re 24: 1869-78, 1988]. Eur. J. Cancer Clin. Oncol., 25: 1259-1260. | Prostate Cancer | 1989 |
| 184. Labrie, F. (1989) Medical treatment of prostate cancer. Drug Therapy, 19: 22-37. | Prostate Cancer | 1989 |
| 75. Labrie, F. (1998) Combined androgen blockade and treatment of localized prostate cancer: a real hope when approaching the year 2000. Endocrine-Related Cancer, 5: 341-351. | Prostate Cancer | 1998 |
| 76. Labrie, F. (1998) Optimizing combined androgen blockade in prostate cancer, in: Belldegrun, A., Kirby, R.S. et Oliver, R.T.D., eds: New Perspectives in Prostate Cancer, England, ISIS Medical Media, pp 293-311. | Prostate Cancer | 1998 |
| 59. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. | Prostate Cancer | 1999 |
| 60. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. | Prostate Cancer | 1999 |
| 2. Labrie, F. (2008) Preface. Best Pract Res Clin Endocrinol Metab, 22: pp. vii-ix. | Prostate Cancer | 2008 |
| 344. Labrie, F., Auclair, C., Cusan, L., Kelly, P.A., Pelletier, G., Ferland, L. (1978) Inhibitory effect of LHRH and its agonists on testicular gonadotropin receptors and spermatogenesis in the rat, in: Hansson, V., ed. 5th Ann. Workshop on the Testis: Endocrine Approach to Male Contraception, Hvidoure, Denmark, Int. J. of Andrology. Scriptor Publisher APS, pp 303-318. | Prostate Cancer | 1978 |
| 340. Labrie, F., Auclair, C., Cusan, L., Lemay, A., Pelletier, G., Kelly, P.A., Bélanger, A., Séguin, C., Raynaud, J.P. (1979) Antifertility effects of LHRH and its agonists in male and female rats: possible luteolytic effects of LHRH in women, in: Talwar, G.P., ed. Recent Advances in Reproduction and Regulation of Fertility, Elsevier-North Holland, Biomedical Press, pp 57-71. | Prostate Cancer | 1979 |
| 305. Labrie, F., Bélanger, A., Carmichael, R., Séguin, C., Lefebvre, F.A., Faure, N., Dupont, A. (1983) Inhibition of the testicular steroidogenic pathway in experimental animals and men, in: D'Agata, R., Lipsett, M.B.,Polosa, P. et van der Molen, H.J., eds: Recent Advances in Male Reproduction: Molecular Basis and Clinical Implications, New York, Raven Press, pp 239-248. | Prostate Cancer | 1983 |
| 334. Labrie, F., Bélanger, A., Cusan, L., Séguin, C., Pelletier, G., Kelly, P.A., Reeves, J.J., Lefebvre, F.A., Lemay, A., Raynaud, J.P. (1980) Antifertility effects of LHRH agonists in the male. J. Androl., 1: 209-228. | Prostate Cancer | 1980 |
| 285. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1984) Combined treatment with an LHRH agonist and a pure antiandrogen in advanced carcinoma of prostate. Lancet, 2: 1090. | Prostate Cancer | 1984 |
| 251. Labrie, F., Bélanger, A., Dupont, A., Emond, J., Lacourcière, Y., Monfette, G. (1986) Cancers évolués de la prostate: traitement par l'association d'un agoniste de la LHRH et d'un antiandrogène pur. J. Int. Med., 66: 367-368. | Prostate Cancer | 1986 |
| 286. Labrie, F., Bélanger, A., Dupont, A., St-Arnaud, R. (1984) Medical castration in men: the first clinical application of LHRH agonists, in: Harrison, R.F. et Thompson, B.J., eds: Fertility and Sterility, MTP Press, pp 25-39. | Prostate Cancer | 1984 |
| 322. Labrie, F., Bélanger, A., Kelly, P.A., Séguin, C., Cusan, L., Lefebvre, F.A., Reeves, J.J., Lemay, A., Faure, N., Laroche, B., Raynaud, J.P. (1981) Antifertility effects of LHRH agonists, in: Soto, R.J., De Nicola, A.F. et Blaquier, J.A., eds: Progress in Clinical and Biological Research. Physiopathology of Diseases and Mechanisms of Hormone Action, New York, Alan R. Liss Inc., pp 273-291. | Prostate Cancer | 1981 |
| 77. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Cusan, L., Gomez, J.L., Candas, B. (1998) DHEA and the intracrine formation of androgens and estrogens in peripheral target tissues: its role during aging. Steroids, 63: 322-328. | Prostate Cancer | 1998 |
| 335. Labrie, F., Bélanger, A., Pelletier, G., Séguin, C., Cusan, L., Kelly, P.A., Lemay, A., Auclair, C., Raynaud, J.P. (1980) LHRH agonists: inhibition of testicular functions and possible clinical applications, in: Cunningham, G.R., Schill, W.B. et Hafez, E.S.E., eds: Clinics in Andrology. Regulation of Male Fertility, The Netherlands, Martinus Nijoff Publ., B.V., The Hague, pp 65-75. | Prostate Cancer | 1980 |
| 323. Labrie, F., Bélanger, A., Séguin, C., Cusan, L., Pelletier, G., Lefebvre, F.A., Kelly, P.A., Ferland, L., Reeves, J.J., Lemay, A., Raynaud, J.P. (1981) Inhibition of testicular and ovarian functions by LHRH agonists, in: Jagiello, G. et Vogel, H.J., eds: Bioregulators of Reproduction, New York, NY, USA, Academic Press, pp 305-341. | Prostate Cancer | 1981 |
| 324. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Kelly, P.A., Lefebvre, F.A., Massicotte, J., Borgus, J.P., Lemay, A., van der Ohe, M. (1981) Antifertility effects of LHRH agonists, in: Semm, K. et Mettler, L., eds: Proc. III World Congress on Human Reproduction, Excerta Medica, ICS 551, pp 116-125. | Prostate Cancer | 1981 |
| 325. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Lefebvre, F.A., Massicotte, J., Kelly, P.A., Borgus, J.P. (1981) LHRH and sexual functions: inhibition at the pituitary and gonadal levels, in: Bizollon, C.A., ed. Physiological peptides and new trends in radioimmunology, Elsevier-North Holland, Biomedical Press, pp 57-70. | Prostate Cancer | 1981 |
| 326. Labrie, F., Bélanger, A., Séguin, C., Pelletier, G., Lefebvre, F.A., Reeves, J.J., Kelly, P.A., Massicotte, J., Cusan, L. (1981) LHRH and down regulation of testicular receptors and function, in: Frajese, G., ed. Oligospermia. Recent Progress in Andrology, New York, NY, USA, Raven Press, pp 337-345. | Prostate Cancer | 1981 |
| 206. Labrie, F., Bélanger, A., Veilleux, R., Lacoste, D., Labrie, C., Marchetti, B., Poulin, R., Dupont, A., Cusan, L., Luthy, I. (1988) Rationale for maximal androgen withdrawal in the therapy of prostate cancer, in: Furr, M. et Denis, L., eds: Baillieres Clinics in Oncology on Prostate Cancer, London, Saunders Company, pp 597-619. | Prostate Cancer | 1988 |
| 99. Labrie, F., Candas, B., Cusan, L., Diamond, P., Gomez, J.L. (1996) Antiandrogen story erred [Letter to the Editor]. The Medical Post, 32: | Prostate Cancer | 1996 |
| 67. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. | Prostate Cancer | 1999 |
| 102. Labrie, F., Cusan, L., Gomez, J.L., Diamond, P., Bélanger, A., Candas, B. (1996) Combination therapy in localized prostate cancer (Chapter 4), in: Schroder, F.H., ed. Recent Advances in Prostate Cancer and BPH, Parthenon Publishing, pp 31-43. | Prostate Cancer | 1996 |
| 336. Labrie, F., Cusan, L., Séguin, C., Bélanger, A., Pelletier, G., Reeves, J., Kelly, P.A., Lemay, A., Raynaud, J.P. (1980) Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man. Int. J. Fertil., 25: 157-170. | Prostate Cancer | 1980 |
| 287. Labrie, F., Dupont, A., Bélanger, A. (1984) Complete androgen neutralization is most important in the treatment of prostate cancer, in: Harrap, K.R., Davis, W. et Calvert, A.H., eds: Cancer Chemotherapy and Selective Drug Development, Martinus Nijihoff Publishing, pp 475-479. | Prostate Cancer | 1984 |
| 288. Labrie, F., Dupont, A., Bélanger, A. (1984) Un nouveau traitement du cancer de la prostate: la suppression complète des androgènes, in: Mauvais-Jarvis, P. et Schaison, G., eds: Médecine de la reproduction masculine, Flammarion, Presses Université de Montréal, pp 367-383. | Prostate Cancer | 1984 |
| 273. Labrie, F., Dupont, A., Bélanger, A. (1985) Complete androgen blockade for the treatment of prostate cancer, in: DeVita, V.T., Hellman, S. et Rosenberg, S.A., eds: Important Advances in Oncology, Philadelphia, J.B. Lippincott, pp 193-217. | Prostate Cancer | 1985 |